| human | Q5 |
| P496 | ORCID iD | 0000-0001-6891-2266 |
| P108 | employer | University of Turku | Q501841 |
| Umeå University | Q1144565 | ||
| Tampere University Hospital | Q11896324 | ||
| P734 | family name | Kampman | Q16863313 |
| Kampman | Q16863313 | ||
| Kampman | Q16863313 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q45933381 | 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. |
| Q37617275 | A cluster model of temperament as an indicator of antidepressant response and symptom severity in major depression. |
| Q51641049 | ACE polymorphism and response to electroconvulsive therapy in major depression. |
| Q50569514 | Acute Psychogeriatric Inpatient Treatment Improves Neuropsychiatric Symptoms but Impairs the Level of Functioning in Patients with Dementia |
| Q39247374 | Anxiety Disorders and Temperament-an Update Review |
| Q47279847 | Apolipoprotein E polymorphism is associated with age of onset in schizophrenia |
| Q33285555 | Association between 5-HT2A, TPH1 and GNB3 genotypes and response to typical neuroleptics: a serotonergic approach |
| Q48726276 | Association between folate intake and melancholic depressive symptoms. A Finnish population-based study |
| Q80263117 | Association between the C957T polymorphism of the dopamine D2 receptor gene and schizophrenia |
| Q34738700 | Association between vitamin b12 levels and melancholic depressive symptoms: a Finnish population-based study |
| Q47642809 | Association of EGF polymorphism with schizophrenia in Finnish men. |
| Q46469930 | Attitudes towards neuroleptic treatment: reliability and validity of the attitudes towards neuroleptic treatment (ANT) questionnaire |
| Q47661605 | BDNF and NRG1 polymorphisms and temperament in selective serotonin reuptake inhibitor-treated patients with major depression |
| Q48109119 | BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression |
| Q35098697 | CYP1A2 polymorphism -1545C > T (rs2470890) is associated with increased side effects to clozapine |
| Q37832049 | Can onset and recovery in depression be predicted by temperament? A systematic review and meta-analysis. |
| Q44603263 | Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia |
| Q80383211 | Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia |
| Q43195469 | Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder |
| Q45372399 | Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine |
| Q44627949 | Dopamine receptor D2 -141C Insertion/Deletion polymorphism in a Finnish population with schizophrenia |
| Q40795242 | Early assessment of implementing evidence-based brief therapy interventions among secondary service psychiatric therapists |
| Q48427429 | Efficacy of electroconvulsive therapy: is it in the BDNF gene? |
| Q47814213 | Factors associated with subjective side-effects during clozapine treatment |
| Q51949789 | Four-year outcome in non-compliant schizophrenia patients treated with or without home-based ambulatory outpatient care. |
| Q88277546 | Genetic Polymorphisms Associated With Constipation and Anticholinergic Symptoms in Patients Receiving Clozapine |
| Q47396785 | Histaminergic gene polymorphisms associated with sedation in clozapine-treated patients |
| Q47255631 | INSIG2 polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine |
| Q74084232 | Indicators of medication compliance in first-episode psychosis |
| Q47678481 | Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics |
| Q44428966 | Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics |
| Q48829855 | Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. |
| Q81187737 | Interaction of tumor necrosis alpha - G308A and epidermal growth factor gene polymorphisms in early-onset schizophrenia |
| Q49122438 | Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? |
| Q54694583 | Lack of association between two polymorphisms of brain-derived neurotrophic factor and response to typical neuroleptics. |
| Q42883293 | Leisure-time physical activity and metabolic syndrome plus depressive symptoms in the FIN-D2D survey |
| Q48720819 | Lifetime leisure-time physical activity and the risk of depressive symptoms at the ages of 65-74 years: the FIN-D2D survey |
| Q35172594 | Meta-analysis of anxiety disorders and temperament |
| Q73470016 | NOTCH4 gene promoter polymorphism is associated with the age of onset in schizophrenia |
| Q80989100 | Neuregulin genotype and medication response in Finnish patients with schizophrenia |
| Q48249396 | No support for a role for BDNF gene polymorphisms rs11030101 and rs61888800 in major depressive disorder or antidepressant response in patients of Finnish origin |
| Q47857713 | One-year follow-up after discontinuing maintenance electroconvulsive therapy |
| Q38885222 | Outcome of patients with dual diagnosis in secondary psychiatric care. |
| Q48907841 | P2RX7 polymorphisms Gln460Arg and His155Tyr are not associated with major depressive disorder or remission after SSRI or ECT. |
| Q80044520 | Patient characteristics and diagnostic discrepancy in first-episode psychosis |
| Q36194480 | Pessimism and risk of death from coronary heart disease among middle-aged and older Finns: an eleven-year follow-up study. |
| Q87672943 | Polymorphism in alpha 2A adrenergic receptor gene is associated with sialorrhea in schizophrenia patients on clozapine treatment |
| Q48798962 | Prevalence of metabolic syndrome in subjects with melancholic and non-melancholic depressive symptoms. A Finnish population-based study |
| Q40680894 | Psychiatric hospital admission and long-term care in patients with very-late-onset schizophrenia-like psychosis |
| Q54609654 | RGS4 genotype is not associated with antipsychotic medication response in schizophrenia. |
| Q81145441 | RGS4 polymorphism and response to electroconvulsive therapy in major depressive disorder |
| Q28391364 | Relationships between depressive symptoms and self-reported unintentional injuries: the cross-sectional population-based FIN-D2D survey |
| Q47931115 | Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine |
| Q48102826 | SERT and NET polymorphisms, temperament and antidepressant response |
| Q48122222 | Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET) gene polymorphisms: susceptibility and treatment response of electroconvulsive therapy in treatment resistant depression |
| Q47173896 | Smoking and weight among patients using clozapine |
| Q117707016 | Socioeconomic factors and use of psychotherapy in common mental disorders predisposing to disability pension |
| Q43252463 | TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response |
| Q34676880 | TPH1 A218C polymorphism and temperament in major depression |
| Q48043753 | Temperament and character profiles associated with depression and treatment response in patients with or without comorbid substance abuse. |
| Q42785023 | Temperament profiles, 5-HT2A genotype, and response to treatment with SSRIs in major depression |
| Q49013653 | Temperament profiles, major depression, and response to treatment with SSRIs in psychiatric outpatients |
| Q88297135 | The effects of adiposity and alcohol use disorder on adipokines and biomarkers of inflammation in depressed patients |
| Q43740088 | The reliability of compliance assessments performed by doctors and patients during neuroleptic treatment: a comparison of compliance ratings |
| Q43086381 | Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression |
| Q77412861 | [Compliance with treatment in schizophrenia and mood disorders] |
| Q81404830 | [Is antipsychotic drug therapy predictable?] |
Search more.